# OnCo record crisantaspase (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/crisantaspase/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "crisantaspase" ;
  schema:name "Crisantaspase (recombinant Erwinia asparaginase)"@en ;
  schema:alternateName "crisantaspase"@en, "Enrylaze"@en, "recombinant Erwinia chrysanthemi asparaginase"@en, "JZP-458"@en, "Enrylaze" ;
  schema:description "Enrylaze is a replacement asparaginase for children and adults with acute lymphoblastic leukaemia or lymphoblastic lymphoma whose bodies have reacted against, or quietly neutralised, the usual E. coli asparaginase. It keeps the asparagine-starving part of their chemotherapy going."@en ;
  schema:url <https://onco.cc/drugs/crisantaspase/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/enrylaze> ;
  onco:status "approved" ;
  onco:tag "ema-register" ;
  onco:modality "Enzyme therapy (recombinant asparaginase)" ;
  onco:approval "EU 2023: ALL and lymphoblastic lymphoma, in a multi-agent regimen, after hypersensitivity or silent inactivation to E. coli-derived asparaginase (adults and children from 1 month)" ;
  onco:related <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/eryaspase/> ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/all-paediatric-standard-risk/>, <https://onco.cc/cancers/all-paediatric-high-risk/> ;
  onco:companies <https://onco.cc/companies/jazz/> .